Syndax Pharmaceuticals, Inc. · NASDAQ:SNDX
Syndax Pharmaceuticals — American Society of Hematology Meeting 2023
68 slides from Syndax Pharmaceuticals's conference presentation, Dec 11, 2023
Slide 1: Syndax Investor Meeting – American Society of Hematology Meeting
Syndax Investor Meeting American Society of Hematology Meeting December 11, 2023
Slide 2: Forward-looking statements disclosure
Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referenci
Slide 3: Welcome and Introduction to Syndax
Welcome and Introduction to Syndax Michael Metzger Chief Executive Officer, Syndax
Slide 4: Syndax: An oncology company with near-commercial heme assets
Syndax: An oncology company with 2 near-commercial heme assets ASH 2023 Plenary and Late-Breaker Two clinically potential first- and best-in-class hematology assets Safety and Efficacy of • Revumenib, novel menin inhibitor, targeting KMT2Ar and mNPM1 acute leukemia Axatilimab at 3 Different Doses in
Slide 5: Axatilimab and revumenib at ASH
Axatilimab and revumenib at ASH Syndax goals at the American Society of Hematology 2023 Annual Meeting Showcase axatilimab and revumenib as potential first- and best-in-class agents with potential as monotherapy and in combination Educate the physician community ahead of expected 2024 launches Gener
Slide 6: Today's guest speakers
Today’s guest speakers Axatilimab (cGVHD) Revumenib (acute leukemia) Eytan Stein, MD Ghayas Issa, MD Vedran Radojcic, MD Chief, Leukemia Service, Assistant Professor, Senior Medical Director and Director, Program for Drug Department of Leukemia, Clinical Leader for Development in Leukemia, Division
Slide 7: Chronic GVHD and Axatilimab Overview
Chronic GVHD and Axatilimab Overview Dr. Vedran Radojcic Senior Medical Director and Clinical Leader for Axatilimab, Syndax Pharmaceuticals
Slide 8: Multiorgan involvement in cGVHD drives morbidity and QOL impairment
Multiorgan involvement in cGVHD drives morbidity and QOL impairment • Chronic GVHD effects up to 50% of allo-HSCT recipients8-10 • Complete responses are rare and many organs respond poorly to available therapy • Patients need prolonged treatment to control disease burden 1. Jagasia MH, et al. Biol
Slide 9: Significant unmet need remains across all lines of therapy
Significant unmet need remains across all lines of therapy If approved, axatilimab will provide a differentiated mechanism from currently approved agents Current Standard of Care1 Corticosteroids are the cornerstone of therapy 1st • ~60% of patients develop corticosteroid Corticosteroids resistance
Slide 10: CSF-1R: The key regulator of macrophage and monocyte functions in cGVHD
CSF-1R: The key regulator of macrophage and monocyte functions in cGVHD Targeting monocyte-derived macrophages may control fibrosis and inflammation • CSF-1/CSF-1R pathway regulates monocyte proliferation and macrophage differentiation and activity1 • CSF-1R signaling is critical for development and
Slide 11: Axatilimab targets key cGVHD pathology mediators
Axatilimab targets key cGVHD pathology mediators • Developing a differentiated, practice- changing intervention in cGVHD • Axatilimab is a monoclonal antibody that targets CSF-1R on monocytes and macrophages1 • Axatilimab inhibits ligand-dependent monocyte and macrophage differentiation and function
Slide 12: Inflammation and fibrosis drive cGVHD
Inflammation and fibrosis drive cGVHD Fibrosis Currently approved agents S J A R inadequately address both inflammation and fibrosis, potentially resulting in Inflammation suboptimal responses Early disease Late disease S Steroid J Jakafi A Axatilimab R Rezurock Through CSF-1R inhibition, axatilimab
Slide 13: Axatilimab is positioned to address what physicians and patients are seeking
Axatilimab is positioned to address what physicians and patients are seeking in a new cGVHD therapy Durable Axatilimab Key responses Attributes • Demonstrates compelling clinical profile Symptomatic Safe and • Unique MOA in cGVHD improvement tolerable Patient • Benefits in fibrotic and inflammatory
Slide 14: Safety and Efficacy of Axatilimab at Different Doses (AGAVE-201)
Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201) Daniel Wolff*, MD, PhD; Corey Cutler,* MD, MPH, FRCPC; Stephanie J. Lee, MD, MPH; Iskra Pusic, MD; Henrique Bittencourt MD, PhD; Jennifer White MD, MSc, FRCPC; Mehdi Hamadani MD; Sal
Slide 15: AGAVE-201: Study Design and Methods
AGAVE-201: Study Design and Methods Key eligibility criteria Primary endpoint • Age ≥2 years with ≥2 prior lines of • ORR in the first 6 cycles as defined by NIH 2014 systemic therapy Consensus Criteria1 • Active cGVHD defined per 2014 NIH • Endpoint was met if lower bound of 95% CI >30% Consensus C
Slide 16: Baseline Characteristics (ITT Population)
Baseline Characteristics (ITT Population) Total cohort Patient characteristic (N=241) Age, median (min, max), y 53 (7, 81) Sex, male, n (%) 151 (63) Race, White, n (%) 200 (83) Time from cGVHD diagnosis to randomization, median (max), y 4 (18) Patients with severe disease, n (%) 192 (80) Number of o
Slide 17: AGAVE-201 positive results in a heavily pretreated, late stage cGVHD population
AGAVE-201 positive results observed in a heavily pretreated, late stage cGVHD population AGAVE-201 ROCKSTAR AGAVE-201 Differentiation Population (ITT) N=132 N=241 Age median (min, max), years 56 (21, 77) 53 (7, 81) Significantly longer time Median time since cGVHD diagnosis 25.3 months 48 months sin
Slide 18: Axatilimab AGAVE-201 Data
Axatilimab AGAVE-201 Data Dr. Daniel Wolff Professor of Hematology, Department of Internal Medicine III of the University of Regensburg
Slide 19: Primary Efficacy Endpoint Met in All Cohorts
Primary Efficacy Endpointa Met in All Cohorts Overall Response Rates With Axatilimab 80 60 Response rate, % 40 74 (95% CI, 63–83) 67 (95% CI, 55–77) 50 20 (95% CI, 39–61) 0 0.3 mg/kg Q2W 1.0 mg/kg Q2W 3.0 mg/kg Q4W n=80 n=81 n=80 Time to response, median 1.7 (0.9–8.1) 1.9 (0.9–8.6) 1.4 (0.9–5.6) mon
Slide 20: Efficacy Across Subgroups in 0.3 mg/kg Q2W
Efficacy Across Subgroups in 0.3 mg/kg Q2W Primary endpoint High response rates (≥75%) were seen in patients who received prior FDA-approved therapies Q2W, every 2 weeks. 20
Slide 21: Organ Responses in 0.3 mg/kg Q2W
Organ Responses in 0.3 mg/kg Q2W 100 89 Complete response 82 Partial response 80 78 76 44% had 13 reduction in BSA Response rate, % involved by 60 sclerosis 52 47 66% had 56 10 89 improvement in 82 40 skin and joint 40 tightening 65 31 30 20 severity 27 20 42 20 17 20 20 16 10 9 0 Lower GI Upper GI
Slide 22: Failure-free Survival in 0.3 mg/kg Q2W
Failure-free Survivala in 0.3 mg/kg Q2W Failure-free survival probability Time to event, months Number of participants at risk Median FFS was 17.3 (95% CI, 14.2–NE) months NE, not estimable; Q2W, every 2 weeks. aDefined as time from randomization to death or new systemic cGVHD therapy, where axatili
Slide 23: Patient-Reported Symptom Burden Change in 0.3 mg/kg Q2W
Patient-Reported Symptom Burden Change in 0.3 mg/kg Q2W Modified Lee Symptom Scale (mLSS) Patient- reported worsening Best change from baseline Patient- reported improvement Individual patients • 55% clinically meaningful change of ≥7-point improvement in mLSS • Median time to ≥7-point mLSS improvem
Slide 24: Axatilimab Safety Profile
Axatilimab Safety Profile Axatilimab Axatilimab Axatilimab 0.3 mg/kg Q2W 1.0 mg/kg Q2W 3.0 mg/kg Q4W n=79 n=81 n=79 Axatilimab dose changes owing to AE, n (%) Discontinuation 5 (6.3) 18 (22.2) 14 (17.7) Dose decrease 5 (6.3) 6 (7.4) 13 (16.5) Any grade AE in ≥20% of total patients Fatigue 18 (22.8)
Slide 25: Conclusion: Axatilimab 0.3 mg/kg Q2W is highly effective
Conclusion: Axatilimab 0.3 mg/kg Q2W is highly effective in patients with recurrent/refractory cGVHD • Responses documented in all organs and patient subgroups, including those with fibrotic cGVHD manifestations • Complete responses observed in all organ systems including the most difficult to treat
Slide 26: Conclusion: Axatilimab 0.3 mg/kg Q2W is well tolerated
Conclusion: Axatilimab 0.3 mg/kg Q2W is well tolerated in patients with recurrent/refractory cGVHD • No unexpected safety concerns • AEs consistent with vulnerabilities of cGHVD patients • Mostly low grade, reversible, and dose dependent • Potential to benefit patients alone or in combination with S
Slide 27: Axatilimab Close and Q&A
Axatilimab Close and Q&A Michael Metzger Chief Executive Officer, Syndax
Slide 28: Axatilimab has the potential to be a differentiated treatment option for cGVHD
Axatilimab has the potential to be a differentiated treatment option for cGHVD Unique MOA for cGVHD High and durable responses • First agent to target disease causing • 74% ORR at 0.3 mg/kg macrophages to impact fibrosis & inflammation • 60% of patients treated at 0.3 mg/kg • Potential synergy with
Slide 29: 2024 & Beyond
Axatilimab has the potential to expand into additional high value indications and new geographies Expansion into fibrotic indications: ~215,000 US IPF POC* init YE23 ~335,000 WW2 2024 & Beyond Expansion into EU, Japan, ROW >35,000 WW1 R/R chronic GVHD: ~14,000 US1 BLA submission expected YE23 2024 P
Slide 30: Acute Leukemia Overview
Acute Leukemia Overview Dr. Eytan Stein Chief, Leukemia Service, Director, Program for Drug Development in Leukemia, Memorial Sloan Kettering Cancer Center
Slide 31: AML treatment paradigm
AML treatment paradigm HSCT AML treatment Frontline Relapsed / Refractory paradigm “Fit” Intensive Chemo Consolidation (Chemo or HSCT) Salvage chemo Or targeted therapy “Unfit for IC” Azacytidine (+ Venetoclax) 31
Slide 32: Treatment response criteria in AML
Treatment response criteria in AML: Tumor clearance equivalent across MLFS and CRc Response Tumor Platelets recovered Neutrophils recovered ORR CRc CR/CRh CR < 5% Yes Yes CRh < 5% Half normal levels Half normal levels CRp < 5% No Yes CRi < 5% Either has recovered MLFS < 5% Neither has recovered 5-25
Slide 33: Measurable residual disease has prognostic implications for clinical practice
Measurable residual disease has prognostic implications for clinical practice Disease Persistence Very Early Relapse Early Relapse Late Relapse Very Late Relapse 1 Morphologic MRD Definition: 10-1 Proportion of Leukemic Cells Disease Microscopic disease detection Cytogenetics Residual leukemia not 1
Slide 34: Treatment goals for patients with relapsed/refractory acute leukemia
Treatment goals for patients with relapsed/refractory acute leukemia Defined by: • Morphologic CR (<5% 1 Eliminate leukemia blasts) may include CR/CRh/CRp/CRi and MLFS • MRD negative CR 34
Slide 35: Treatment goals for patients with relapsed/refractory acute leukemia
Treatment goals for patients with relapsed/refractory acute leukemia Defined by: • Morphologic CR (<5% 1 Eliminate leukemia blasts) may include CR/CRh/CRp/CRi and MLFS YES Transplant eligible? NO • MRD negative CR Maintain remission and: Allogeneic HSCT 2 Avoid infections 3 Minimize transfusions 4 M
Slide 36: Goals and rationale for transplantation
HSCT Goals and rationale for transplantation Allogeneic HSCT is the only known method to completely cure AML Step 1: Step 2: Step 3: Marrow cleared Conditioning* Bone marrow to ≤ 5% tumor performed to or peripheral blast count ablate bone blood stem- (CRc or MLFS); marrow and cell graft & BM donor e
Slide 37: Treatment options are needed for patients with KMT2Ar and mNPM1 acute leukemias
Despite recent advances in AML and ALL, treatment options are needed for patients with KMT2Ar and mNPM1 acute leukemias KMT2Ar Acute Leukemia NPM1 Mutant AML 10% of AML or ALL1 30% of AML2 Revumenib has demonstrated positive clinical results in both Most patients relapse after Most frequent genetic
Slide 38: Revumenib is positioned to deliver on key metrics
Revumenib is positioned to deliver on key metrics that would address the needs of patients Revumenib Key Response Attributes • Demonstrates encouraging clinical profile Overall MRD-negative survival • Overall treatment profile Patient that enables R/R to receive HSCT, and post-Tx maintenance • Conve
Slide 39: AUGMENT-101 and SAVE Trial Results
AUGMENT-101 and SAVE Trial Results Dr. Ghayas Issa Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Slide 40: Pivotal AUGMENT-101 trial design
Pivotal AUGMENT-101 in KMT2Ar and mNPM1 acute leukemias trial design Phase 1 Phase 2 Dose Escalation Ongoing Pivotal Trials KMT2Ar AUGMENT-101-2A: KMT2Ar ALL AUGMENT-101-2B: KMT2Ar AML Adult and ped1 with R/R KMT2Ar RP2D2 or mNPM1 acute leukemia mNPM1 AUGMENT-101-2C: mNPM1 AML Primary endpoint CR Ra
Slide 41: Demographics and design of KMT2Ar patients in AUGMENT-101 Phase 1
Demographics and design of KMT2Ar patients enrolled into AUGMENT-101 Phase 1 trial ASH23 #2907 Demographics Phase 1 KMT2Ar population Efficacy Safety Phase 1 Adult AML ALL / Otherb Pedsc KMT2Ar population Parameter (n=51) (n=15) (n=15) (n=77) (n=132) Dose Escalation Median age, y (range) 40.0 34
Slide 42: In Phase 1, KMT2Ar patients experienced strong response to revumenib
In Phase 1, KMT2Ar patients experienced strong response to revumenib ASH23 #2907 Efficacy (KMT2Ar acute leukemia) Safety (all patients) Adult AML ALL/Other Pedsc Overall All terms Safety pop (n=132) Parameter (n=51) (n=15) (n=15) KMT2Ar (n=77) Any grade TEAE, n (%) 128 (97) ORR, n (%) 35 (69)
Slide 43: Phase 1 R/R mNPM1 patients achieve durable, MRD-negative responses
AUGMENT-101: Phase 1 R/R mNPM1 patients achieve durable, MRD-negative responses with revumenib CR/CRh Transplant CR/CRh MLFS n (%) # of prior Tx Transplant PD Total mNPM1 @ RP2D 14 2 MRD(-) CR/CRh Æ MLFS Æ Follow-up ongoing 2 MRD(-) CR/CRh PD CR/CRh 5 (36%) 2 MRD(-) CR/CRh Æ Æ Response Follow-up ong
Slide 44: AUGMENT-101 KMT2Ar data shows high rate of durable, MRDneg responses
AUGMENT-101 KMT2Ar data shows a high rate of durable, MRDneg responses ASH23 #LBA5 Enables deep, durable responses in late line R/R acute leukemia Overall response rate 63% in pooled analysis Enables a high rate of deep, durable MRDneg responses in late line R/R patients 23% CR/CRh rate in pooled an
Slide 45: Post-transplant maintenance experience supports long-term revumenib use
Post-transplant maintenance experience supports long-term revumenib use ASH23 #4950 # prior Prior Last response TRAE leading to dose modification post Age regimens HSCT (#)a reportedb HSCT 22 4 Yes (2) MRD− (BM)c Decreased: leg pain > 40 1 Yes (1) CR, MRD− Decreased: thrombocytopenia 11 3 No CR, MRD
Slide 46: Thought leaders indicate revumenib may change the treatment paradigm
Thought leaders indicate revumenib may change the treatment paradigm for R/R KMT2Ar acute leukemia ASH23 #4950 Anticipated KMT2Ar treatment paradigm upon revumenib approval Revumenib Revumenib HSCT maintenance Relapsed or Refractory 63% respond 39% receive 71% received or (n = 57) (36/57) transplant
Slide 47: Revumenib is evolving the AML treatment paradigm
Revumenib is evolving the AML treatment paradigm HSCT AML treatment Relapsed / Frontline paradigm Refractory Intensive Consolidation Salvage HSCT “Fit” Chemo (Chemo or HSCT) chemo Post- or transplant targeted Maintenance “Unfit for IC” Azacytidine (+ Venetoclax) therapy 47
Slide 48: SAVE AML: Revumenib plus Ven/HMA combo
SAVE AML: Revumenib plus Ven/HMA combo in R/R mNPM1, NUP98r or KMT2Ar AML/MPAL ASH23 #58 Phase 1 in R/R mNPM1, NUP98r or KMT2Ar AML/MPAL Revumenib + venetoclax + decitabine/cedazuridine (ASTX727) Primary Endpoints: Safety, MTD, RP2D of combination DL0: DL1: Revumenib*: 113 mg q12h Revumenib*: 163 mg
Slide 49: 100% ORR for patients treated with Revumenib/Venetoclax/Decitabine
100% ORR for patients treated with Revumenib/Venetoclax/Decitibine ASH23 #58 Summary of Enrolled Patients & Response Data • 100% Response rate in heavily pre-treated pts N (%) Subtype KMT2Ar: 5; mNPM1: 1 • 67% received prior HMA and/or prior HSCT Total enrolled 9 NUP98r: 3 • 56% of patients enrolled
Slide 50: SAVE AML supports favorable safety and tolerability profile
SAVE AML supports favorable safety and tolerability profile of all-oral revumenib-venetoclax-decitabine/cedazurine combo in R/R acute leukemia ASH23 #58 SAVE trial safety summary Treatment Related AEs All Grades in ≥25% Grade ≥3 • No discontinuations for TRAEs, Hyperphosphatemia 56% -- No ≥ Gr 3 QTc
Slide 51: SAVE AML leads to rapid responses in refractory cases
SAVE AML leads to rapid responses in refractory cases ASH23 #58 Prior Therapies HSCT HMA Ven Menin-i + - - - - - + - + + + - + + + + - + + - + + - - - - - - + + - - Median follow-up of 6.4 months Median time to response 28 days + + + - Treatment duration (mo) 5 patients received HSCT consolidation 2
Slide 52: SAVE AML early results indicate durable remissions
SAVE AML early results indicate durable remissions ASH23 #58 Median RFS and OS not reached with 2 patients having ongoing remission beyond 11 months Data Cutoff Nov 01, 2023 52
Slide 53: BEAT AML Trial Results
BEAT AML Trial Results Dr. Joshua Zeidner, MD Associate Professor of Medicine, Chief, Leukemia Research, University of North Carolina, Lineberger Comprehensive Cancer Center
Slide 54: BEAT-AML and Syndax partnered on frontline SOC combos
BEAT-AML and Syndax partnered on frontline SOC combos based on strong efficacy and tolerability observed in relapsed / refractory patients HSCT AML treatment Frontline Relapsed / Refractory paradigm “Fit” Intensive Chemo Consolidation (Chemo or HSCT) Salvage chemo Or targeted therapy “Unfit for IC”
Slide 55: VIALE-A trial establishes the SOC for newly diagnosed AML
VIALE-A trial establishes the SOC for treatment of newly diagnosed AML patients unable to tolerate intensive chemotherapy VIALE-A: Ph3, RCT to evaluate the efficacy and safety of azacitidine plus venetoclax vs azacitidine alone • Median Overall Survival -- 14.7 mo (Primary Endpoint) • Composite Comp
Slide 56: BEAT AML: Revumenib + Ven/Aza combo in frontline AML
BEAT AML: Revumenib +Ven/Aza combo in frontline mNPM1 or KMT2Ar AML Phase 1 Revumenib + azacitidine + venetoclax Induction Continue Revumenib treatment Marrow indefinitely; until (DL1a or DL2a) Patients ≥ 60 yr remission progression, old and unfit for + Azacitidine transplant, intensive chemo (75 mg
Slide 57: BEAT AML patient demographics
BEAT AML patient demographics Dose Level 1a Dose Level 2a Total n=7 n=6 n = 13 Median Age (yrs), (range) 67 (61-85) 75 (65-84) 73 (61-85) Age ≥75 years, % (n) 43% (3) 17% (1) 4 (31) Gender, % M 14% 83% 46% NPM1 mut, % (n) 57% (4) 66% (4) 62% (8) KMT2Ar, % (n) 43% (3) 33% (2) 38% (5) BM Blasts, % (ra
Slide 58: Newly diagnosed patients achieved CRc within 1-2 cycles of induction
Newly diagnosed mNPM1 or KMT2Ar AML patients achieved CRc within 1-2 cycles of induction with the triplet combination of rev-ven-aza 113 mg q12h 163 mg q12h All Treated Dose Level 1a Dose Level 2a Patients KMT2Ar mNPM1 KMT2Ar mNPM1 (DL1a + DL2a) Total # Patients 3 4 2 4 13 Best Response CRc 3 (100%)
Slide 59: BEAT-AML safety and status
BEAT-AML safety and status • Cytopenias manageable with continuous dosing of venetoclax and full dose revumenib • Triplet has cleared DLT window for • 1 Hematologic DLT observed in DL1a: platelets exceeded 42 both revumenib days to recover, no other DLTs across both dose levels dose levels • 4/13 (3
Slide 60: AUGMENT-102 Trial Results
AUGMENT-102 Trial Results Dr. Neerav Shukla, MD Chief, Pediatric Translational Medicine Service at Memorial Sloan Kettering Cancer Center
Slide 61: AUGMENT-102: Revumenib plus FLA combo
AUGMENT-102: Revumenib plus FLA combo in R/R mNPM1, NUP98r or KMT2Ar AML Phase 1 in R/R mNPM1, NUP98r or KMT2Ar Acute Leukemia Revumenib + fludarabine + cytarabine Primary Endpoints: Safety, MTD, RP2D of combination DL0: DL1: Revumenib*: 113 mg q12h Revumenib*: 163 mg q12h Fludarabine: 30 mg/m2 QD D
Slide 62: Safety and tolerability data with FLA combinations in R/R AML
Safety and tolerability data observed with fludarabine-cytarabine (FLA) combinations in patients with R/R AML First relapse or primary refractory First relapse adult AML with leukemia Pediatric AML treated with FLAG1 following 1 course of mitoxantrone-etoposide treated with FLA2 Grade 3 or 4 toxicit
Slide 63: AUGMENT-102 shows benefit in chemo combo (FLA)
AUGMENT-102 shows benefit in chemo combo (FLA) in late line R/R KMT2Ar, mNPM1 or NUP98r AML without added AEs Demographics Efficacy Results Safety summary Total evaluable DL1 DL2 Total evaluable DL1 DL2 Gr ≥3 revumenib % (N=3) (N=12) (N=3) (N=12) treatment-related AEs N=15 Median age 20 yrs 4 yrs Pl
Slide 64: AUGMENT-102 Summary
AUGMENT-102 Summary • AUGMENT-102 Phase 1 trial examined the safety of revumenib in combination with standard AML salvage chemotherapy (FLA – fludarabine-cytarabine) • AE profile was consistent with intensive chemo in R/R AML • 50% of patients in the trial already failed prior FLA • 33% CRc rate exc
Slide 65: Close and Q&A
Close and Q&A Michael Metzger Chief Executive Officer, Syndax
Slide 66: Revumenib is a potential first- and best-in-class therapy
xxx Revumenib is a potential first- and best-in-class therapy for KMT2Ar and Response mNPM1 acute leukemia Positive monotherapy results to date: • Clinically meaningful efficacy data in R/R KMT2Ar acute Durability MRD-negative leukemia; mNPM1 results consistent with KMT2Ar Patient • Durable response
Slide 67: Revumenib's profile supports use as backbone therapy across treatment continuum
Revumenib’s profile supports use as backbone therapy across treatment continuum — providing access to >$4B US market opportunity Significant growth potential with indications in earlier lines of treatment ~ $2B market > $4B market Market Opportunity ($ B) ~ $1B market ~ $1.5 - $2B market R/R 1L “Unf
Slide 68: TON
ry, TON
Syndax Pharmaceuticals — American Society of Hematology Meeting 2023 on 6ix